5

WHAT IS CLAIMED IS:

- 1. A method of revitalizing hair growth which comprises: administering to an animal an effective amount of a non-immunosuppressive pyrrolidine carboxylate compound.
- 2. The method of claim 1 wherein the pyrrolidine carboxylate is a compound of the formula:

I

wherein

R is selected from the group consisting of a C_1 - C_9 straight or branched chain alkyl or alkenyl group optionally substituted with C_3 - C_8 cycloalkyl, C_3 or C_5 cycloalkyl, C_5 - C_7 cycloalkenyl, Ar_1 , where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C_1 - C_4 alkyl, C_1 - C_4 alkenyl, or hydroxy, where Ar_1 is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkeryloxy, phenoxy,

benzyloxy, and amino:

25

5

10

- X is selected from the group consisting of oxygen, sulphur, methylene (CH₂), or H₂;
- Y is selected from the group consisting of oxygen or NR_2 , where R_2 is hydrogen or C^1 - C_4 alkyl; and
- Z is selected from the group consisting of C_2 - C_6 straight or branched chain alkyl or alkenyl,

wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_3 - C_8 cycloalkyl, cycloalkyl connected by a C_1 - C_8 straight or unbranched alkyl- or alkenyl chain, and Ar_2 is selected from the group consisting of 2 indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_6 alkenyloxy, phenoxy, benzyloxy, and amino; Z may also be the fragment:

wherein

- R_3 is a C_1 - C_9 straight or branched alkyl $\#_1$ - C_8 optionally substituted with C_3 - C_8 cycloalkyl, or Ar_1 as defined above, and unsubstituted Ar_1 ;
- K_2 is 0 or NR_5 , where R_5 is selected from the group consisting of hydrogen, $C_1\text{-}C_6$ straight or branched alkyl and alkenyl;

5

- R_4 is selected from the group consisting of phenyl, benzyl, C_1 - C_5 straight or branched alkyl or alkenyl, and C_1 - C_5 straight or branched alkyl or alkenyl substituted with phenyl; or pharmaceutically acceptable salts or hydrates thereof.
- 3. The method of claim 1 wherein the pyrrolidine carboxylate is a compound of the formula:

II

wherein

is a C₁-C₉ straight or branched chain alkyl or alkenyl group optionally substituted with C₃-C₃ cycloalkyl, C₃ or C₅ cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁, where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl, or hydroxy, and where Ar₁ is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched alkyl or alkenyl, C₁-C₄ alkoxy or C₁-C₄ alkenyloxy, phenoxy, benzyloxy, and amino;

IJ

Z

- is a C₂-C₆ straight or branched chain alkyl or alkenyl, wherein the alkyl chain is substituted in one or more positions with Ar₁ as defined above, C₁-C₈ cycloalkyl, cycloalkyl connected by a C₁-C₆ straight or unbranched alkyl or alkenyl chain, or Ar₂, where Ar₂ is selected from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro trifluoromethyl, C₁-C₆ straight or branched alkyl or alkenyl, C₁-C₄ alkoxy or C₁-C₄ alkenyloxy, phenoxy, benzyloxy, and amino; or pharmaceutically acceptable salts or hydrates thereof.
- 4. The method of claim 1 wherein the pyrrolidine carboxylate compound is selected from the group consisting of:

 3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
- 3-phenyl-1-prop-2-(E)-enyl (2S)-1-(3,3,-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
- 3-(3,4,5-trimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
- 3-(3,4,5-trimethoxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
- 3-(4,5-methylenedioxyphenyl)-1-propyl(2S)-1-(3,3,dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
 - 3-(4,5-methylenedioxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

```
pyrrolidinecarpoxylate,
       3-cyclohexyl-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-
      dioxopentyl) -2-pyrrolidinecarboxylate,
 5
      (1R)-1,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-
      dioxopentyl) - 2 - pyrrolidinecarboxylate,
       3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-furanyl])ethyl-2-
      pyrrolidinecarboxylate,
       3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thienyl])entyl-2-
10
      pyrrolidinecarboxylate.
       3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thiazolyl])ethyl-2-
pyrrolidinecarboxylate,
3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2,phenyl)ethyl-2-
      pyrrolidinecarboxylate,
       3-(2,5-dimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-
dioxopentyl) - 2 - pyrrolidinecarboxylate,
       3-(2,5-dimethoxyphenyl)-1-prop-2-(E)-enyl(2S)-1-(3,3-dimethyl-
      1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
[]
       2-(3,4,5-trimethoxyphenyl)-1-ethyl (2S)-1-(3,3-dimethyl-1,2-
20
      dioxopentyl) - 2 - pyrrolidinecarboxylate,
       3-(3-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
      pyrrolidinecarboxylate,
       3-(2-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
      pyrrolidinecarboxylate,
       3-(4-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
25
      pyrrolidinecarboxylate,
       3-phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-
```

3-cyclohexyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-

pyrrolidinecarboxylate,

```
CO the first limit the first limit and the first limit that the first limit that the first section of the first limit that the first li
```

- 3-phenyl-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
- 3-phenyl-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
- 5 3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
 - 3-(3-Pyridyl)-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
 - 3,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
 - 3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
 - 3-(3-Pyridyl)-1-propyl (2S)-N-([2-thienyl]glyoxyl) pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxobutyl)-2-pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-cyclohexylglyoxyl-2-pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-(2-thienyl)glyoxyl-2-pyrrolidinecarboxylate) and pharmaceutically acceptable salts, hydrates, and mixtures thereof.
 - 5. A method of promoting hair germination which comprises: administering to an animal an effective amount of a non-immunosuppressive pyrrolidine carboxylate compound.

25

5

6. The method of claim 5 wherein the pyrrolidine carboxylate is a compound of the formula:

wherein

 R_1 is selected from the group consisting of a C_1 - C_9 straight or branched chain alkyl or alkenyl group optionally substituted with C_3 - C_9 cycloalkyl, C_3 or C_9 cycloalkyl, C_9 - C_9 cycloalkenyl, Ar_1 , where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C_1 - C_4 alkyl, C_1 - C_4 alkenyl, or hydroxy, where Ar_1 is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-,3-,4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_9 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino:

- X is selected from the group consisting of oxygen, sulfur, methylene (CH $_2$) or H $_2$;
- Y is selected from the group consisting of oxygen or NR_2 , where R_2 is hydrogen or C^1 - C_5 alkyl; and
- Z is selected from the group consisting of C_2 - C_6 straight

or branched chain alkyl or alkenyl,

wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_3 - C_6 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight-or-unbranched alkyl or alkeryl chain, and Ar_2 is selected from the group consisting of 2-indolyl 3-indolyl, 2-furyl, 3-furyl, 2-thiazelyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino; Z_1

may also be the fragment:

wherein

5

10

20 -

- R_3 is a C_1 - C_9 straight or branched alkyl $\#_1$ - C_8 optionally substituted with C_3 - C_9 cycloalkyl, or Ar_1 as defined above, and unsubstituted Ar_1 ;
- $\rm K_2$ is O or NR₅, where R₅ is selected from the group consisting of hydrogen, C₁-C₆ straight or branched alkyl and alkenyl;
- R₄ is selected from the group consisting of phenyl, benzyl, C_1 - C_5 straight or branched alkyl or alkenyl, and C_1 - C_5 straight or branched alkyl or alkenyl substituted with phenyl; or pharmaceutically acceptable salts or hydrates thereof.

7. The method of claim 5 wherein the pyrrolidine carboxylate is a compound of the formula:

wherein

 R_{1}

 \mathbb{Z}

..........

5

The state of the s

15

is a C₁-C₂ straight or branched chain alkyl or alkenyl group optionally substituted with C3-C9 cycloalkyl, C3 or C₅ cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁, where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C1-C2 alkyl, C1-C2 alkenyl, or hydroxy, and where Ar; is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, substituents having one to three which independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched alkyl or alkenyl, C.-C. alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino;

II

is a C_2 - C_6 straight or branched chain alkyl or alkenyl, wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_2 - C_8 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight or unbranched

alkyl or alkenyl chain, (or Ar2 where Ar2 is selected

5

10

from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino; or pharmaceutically acceptable salts or hydrates thereof.

8. The method of claim 5 wherein the pyrrolidine carboxylate is selected from the group consisting of:

3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-phenyl-1-prop-2-(E)-enyl (2S)-1-(3,3,-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(3,4,5-trimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(3,4,5-trimethoxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(4,5-methylenedioxyphenyl)-1-propyl(2S)-1-(3,3,dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(4,5-methylenedioxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-dicxopentyl)-2-pyrrolidinecarboxylate,

3-cyclohexyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-cyclohexyl-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

(1R)-1,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-

```
dioxopentyl) - 2 - pyrrolidinecarboxylate,
                 3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-furanyl])ethyl-2-
               pyrrolidinecarboxylate,
                 3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thienyl])entyl-2-
  5
              pyrrolidinecarboxylate,
                 3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thiazolyl])ethyl-2-
               pyrrolidinecarboxylate,
                                                                           (2S)-1-(1,2-dioxo-2,phenyl)ethyl-2-
                  3-phenyl-1-propyl
               pyrrolidinecarboxylate,
                  3-(2,5-dimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-
10
               dioxopentyl)-2-pyrrolidinecarboxylate,
                  3-(2,5-dimethoxyphenyl)-1-prop-2-(E)-enyl(2S)-1-(3,3-dimethyl-
100
The trial from such that the first the first that will be to the first
                1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
                  2-(3,4,5-trimethoxyphenyl)-1-ethyl (2S)-1-(3,3-dimethyl-1,2-
                dioxopentyl)-2-pyrrolidinecarboxylate,
                  3-(3-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                pyrrolidinecarboxylate,
                   3-(2-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                pyrrolidinecarboxylate,
20
                   3-(4-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                pyrrolidinecarboxylate,
                   3-phenyl-1-propyl (25)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-
                pyrrolidinecarboxylate,
                   3-phenyl-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-
 25
                pyrrolidinecarboxylate,
                   3-phenyl-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-dioxoethyl)-2-
                pyrrolidinecarboxylate,
                   3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-
```

dioxoethyl) -2-pyrrolidinecarboxylate,

- 3-(3-Pyridyl)-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
- 3,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
- 3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
- 3-(3-Pyridyl)-1-propyl (2S)-N-([2-thienyl]glyoxyl) pyrrolidinecarboxylate,
- 3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxobutyl)-2-pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-cyclohexylglyoxyl-2-pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-(2-thieryl)glyoxyl-2-pyrrolidinecarboxylate, and pharmaceutically acceptable salts, hydrates, or mixtures thereof.
 - 9. A method of preventing hair loss which comprises: administering to an animal an effective amount of a non-immunosuppressive pyrrolidine carboxylate compound.
 - 10. The method of claim 9 wherein the pyrrolidine carboxylate is a compound of the formula:

$$\begin{array}{c|c}
 & Y & Z \\
 & X & Y & Z
\end{array}$$

wherein

5

13

The street same than the street that the street street the street street

20

I

25

10

5

 R_1 is selected from the group consisting of a C_1 - C_9 straight or branched chain alkyl or alkenyl group optionally substituted with C_3 - C_9 cycloalkyl, C_5 or C_9 cycloalkyl, C_5 - C_7 cycloalkenyl, Ar_1 , where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C_1 - C_4 alkyl, C_1 - C_4 alkenyl, or hydroxy, where Ar_1 is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_9 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino:

- X is selected from the group consisting of oxygen, sulfur, methylene (CH_2), or H_2 ;
- Y is selected from the group consisting of oxygen or NR_2 , where R_2 is hydrogen or $C^1\text{-}C_6$ alkyl; and
- Z is selected from the group consisting of C_2 - C_6 straight or branched chain alkyl or alkenyl,

wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_3 - C_8 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight or unbranched alkyl or alkenyl chain, and Ar_2 is selected from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro,

trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino; Z may also be the fragment:

5 wherein

O the continue of the set has a few part and the

- R₃ is a C₁-C₉ straight or branched alky $\frac{1}{4}$ #₁-C₈ optionally substituted with C₃-C₆ cycloalkyI, or Ar₁ as defined above, and unsubstituted Ar₁;
- $\rm X_2$ is 0 or NR_5, where $\rm R_5$ is selected from the group consisting of hydrogen, $\rm C_1\text{-}C_6$ straight or branched alkyl and alkenyl;
- R, is selected from the group consisting of phenyl, benzyl, C_1 - C_5 straight or branched alkyl or alkenyl, and C_1 - C_5 straight or branched alkyl or alkenyl substituted with phenyl; or pharmaceutically acceptable salts or hydrates—thereof.

11. The method of claim 9 wherein the pyrrolidine carboxylate is a compound of the formula:

$$0 = \sum_{R} 0 = Z$$

20 wherein

II

5

10

 \mathbb{R}_{1}

 \mathbb{Z}

is a C1-C, straight or branched chain alkyl or alkenyl group optionally substituted with C.-C. cycloalkyl, C, or C, cycloalkyl, C,-C, cycloalkenyl, or Ar,, where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C.-C. alkvl, C.-C. alkenyl, or hydroxy, and where Ar, is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, three substituents having one CO independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C,-Cs straight or branched alkyl or alkenyl, C,-C, alkoxy or C₁-C₄ alkenyloxy, phenoxy, benzyloxy, and amino;

is a C_2 - C_6 straight or branched chain alkyl or alkenyl, wherein the arkyl chain is substituted in one or more positions with Ar_1 as defined above, C_3 - C_6 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight or unbranched alkyl or alkenyl chain, or Ar_2 where Ar_2 is selected from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phanyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino; or pharmaceutically acceptable salts or hydrates thereof.

```
carboxylate is selected from the group consisting of:
      3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
     pyrrolidinecarboxylate,
      3-phenyl-1-prop-2-(E)-enyl (2S)-1-(3,3,-dimethyl-1,2-
5
     dioxopentyl) - 2 - pyrrolidinecarboxylate,
      3-(3,4,5-trimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-
     dioxopentyl) - 2 - pyrrolidinecarboxylate,
     = 3 - (3,4,5-trimethoxyphenyl) - 1-prop - 2-(E) - enyl (2S) - 1-(3,3-1)
10
    dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
      3-(4,5-methylenedioxyphenyl)-1-propyl(2S)-1-(3,3,dimethyl-1,2-
     dioxopentyl) -2-pyrrolidinecarboxylate,
      3-(4,5-methylenedicxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-
 dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
 £3
154
       3-cyclohexyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
 pyrrolidinecarboxylate,
       3-cyclohexyl-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-
      dioxopentyl) - 2 - pyrrolidinecarboxylate,
 H.
 13
       (1R)-1,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-
 i.
20
      dioxopentyl) - 2 - pyrrolidinecarboxylate,
       3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-furanyl])ethyl-2-
      pyrrolidinecarboxylate,
    3-phenyl-1-propyl (25)-1-(1,2-dioxo-2-[2-thienyl])entyl-2-
      pyrrolidinecarboxylate,
       3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thiazolyl])ethyl-2-
2.5
     pyrrolidinecarboxylate,
```

12. The method of claim 9 wherein the pyrrolidine

pyrrolidinecarboxylate,

3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2,phenyl)ethyl-2-

```
dioxopentyl) - 2 - pyrrolidinecarboxylate,
                   3-(2,5-dimethoxyphenyl)-1-prop-2-(E)-enyl(2S)-1-(3,3-dimethyl-
                1,2-dloxopentyl)-2-pyrrolidinecarboxylate,
 5
                   2-(3,4,5-trimethoxyphenyl)-1-ethyl (2S)-1-(3,3-dimethyl-1,2-
                dioxopentyl) - 2 - pyrrolidinecarboxylate,
                   3-(3-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                pyrrolidinecarboxylate,
                    3-(2-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
10
                pyrrolidinecarboxylate,
                    3-(4-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                pyrrolidinecarboxylate,
   1.1
P-1
                    3-phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-
                pyrrolidinecarboxylate,
                    3-phenyl-1-propyl (2S) -1-(2-tert-butyl-1,2-dioxoethyl)-2-
   gram tyring it given its special section of the sec
                 pyrrolidinecarboxylate,
                    3-phenyl-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-dioxoethyl)-2-
                 pyrrolidinecarboxylate,
                    3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-
20
                 dioxoethyl) - 2 - pyrrolidinecarboxylate,
                    3-(3-Pyridyl)-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-
                 pyrrolidinecarboxylate,
                     3,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                 pyrrolidinecarboxylate,
 25
                     3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-
```

3-(2,5-dimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-

3-(3-Pyridyl)-1-propyl (2S)-N-([2-thienyl]glyoxyl)

pyrrolidinecarboxylate,

pyrrolidinecarboxylate,

- 3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxobutyl)-2-pyrrolidinecarboxylate,
- 3,3-Diphenyl-1-propyl (2S)-1-cyclohexylglyoxyl-2-pyrrolidinecarboxylate, .
- 3,3-Diphenyl-1-propyl (25)-1-(2-thienyl)glyoxyl-2-pyrrolidinecarboxylate, or pharmaceutically acceptable salts, hydrates, and mixtures thereof.

administering to an animal an effective amount of a nonimmunosuppressive pyrrolidine carboxylate compound.

14. The method of claim 13 wherein the pyrrolidine carboxylate is a compound of the formula:

wherein

15

20

 R_1 is selected from the group consisting of a C_1 - C_9 straight or branched chain alkyl or alkenyl group optionally substituted with C_3 - C_8 cycloalkyl, C_3 or C_5 cycloalkyl, C_5 - C_7 cycloalkenyl, Ar_1 , where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C_1 - C_4 alkyl, C_1 - C_4 alkenyl, or hydroxy, where Ar_1 is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl,

 $\overline{}$

10

having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C^1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino:

- X is selected from the group consisting of oxygen, sulphur, methylene (CH_2) , or H_2 ;
- Y is selected from the group consisting of oxygen or NR2, where R2 is hydrogen or C^1-C_6 alkyl; and
- Z is selected from the group consisting of $C_2\text{-}C_6$ straight or branched chain alkyl or alkenyl,

wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_3 - C_8 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight or unbranched alkyl or alkenyl chain, and Ar_2 is selected from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino; Z may also be the fragment:

wherein

25 R_3 is a C_1 - C_9 straight or branched alkyl $\#_1$ - C_8

optionally substituted with C_3 - C_8 cycloalkyl, or Ar_1 as defined above, and unsubstituted Ar_1 ;

- X_2 is 0 or NR_5 , where R_5 is selected from the group consisting of hydrogen, $C_1\text{-}C_6$ straight or branched alkyl and alkenyl;
- R_4 is selected from the group consisting of phenyl, benzyl, C_1 - C_5 straight or branched alkyl or alkenyl, and C_1 - C_5 straight or branched alkyl or alkenyl substituted with phenyl; or pharmaceutically acceptable salts or hydrates thereof.
- 15. The method of claim 13 wherein the pyrrolidine carboxylate is a compound of the formula:

wherein

5

15

20

is a C₁-C₉ straight or branched chain alkyl or alkenyl group optionally substituted with C₃-C₃ cycloalkyl, C₃ or C₅ cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁, where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl, or hydroxy, and where Ar₁ is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl,

20

25

having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino;

is a C₂-C₆ straight or branched chain alkyl or alkenyl, wherein the alkyl chain is substituted in one or more positions with Ar₁ as defined above, C₃-C₈ cycloalkyl, cycloalkyl connected by a C₁-C₆ straight or unbranched alkyl or alkenyl chain, or Ar₂ where Ar₂ is selected from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro trifluoromethyl, C₁-C₆ straight or branched alkyl or alkenyl, C₁-C₄ alkoxy or C₁-C₄ alkenyloxy, phenoxy, benzyloxy, and amino; or pharmaceutically acceptable salts or hydrates thereof.

carboxylate compound is selected from the group consisting of:

3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2pyrrolidinecarboxylate,

3-phenyl-1-prop-2-(E)-enyl (2S)-1-(3,3,-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(3,4,5-trimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(3,4,5-trimethoxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-

```
dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
      3-(4,5-methylenedioxyphenyl)-1-propyl(2S)-1-(3,3,dimethyl-1,2-
     dioxopentyl) - 2 - pyrrolidinecarboxylate,
      3-(4,5-methylenedioxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-
5
     dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
      3-cyclohexyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
     pyrrolidinecarboxylate,
       3-cyclohexyl-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-
     dioxopentyl) -2-pyrrolidinecarboxylate,
10
       (1R)-1,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-
      dioxopentyl) - 2 - pyrrolidinecarboxylate,
       3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-furanyl])ethyl-2-
 Įij.
      pyrrolidinecarboxylate,
 3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thienyl])entyl-2-
 M
154
      pyrrolidinecarboxylate,
 Į.
       3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thiazolyl])ethyl-2-
      pyrrolidinecarboxylate,
       3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2,phenyl)ethyl-2-
      pyrrolidinecarboxylate,
20
       3-(2,5-dimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-
      dioxopentyl) -2-pyrrolidinecarboxylate,
       3-(2,5-dimethoxyphenyl)-1-prop-2-(E)-enyl(2S)-1-(3,3-dimethyl-
      1,2-dioxopenty1)-2-pyrrolidinecarboxylate,
       2-(3,4,5-trimethoxyphenyl)-1-ethyl (2S)-1-(3,3-dimethyl-1,2-
25
      dioxopentyl) - 2 - pyrrolidinecarboxylate,
       3-(3-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
      pyrrolidinecarboxylate,
       3-(2-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
```

```
15]
    tions form street deep gives
```

```
pyrrolidinecarboxylate,
       3-(4-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
      pyrrolidinecarboxylate,
       3-phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-
. 5
      pyrrolidinecarboxylate,
       3-phenvl-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-
      pyrrolidinecarboxylate,
       3-pheryl-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-dioxoethyl)-2-
      pyrrolidinecarboxylate,
10
       3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-
      dioxoethyl) -2-pyrrolidinecarboxylate,
       3-(3-Pvridyl)-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-
      pyrrolidinecarboxylate,
       3,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
      pyrrolidinecarboxylate,
       3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-
      pyrrolidinecarboxylate,
        3-(3-Pyridyl)-1-propyl (2S)-N-([2-thienyl]glyoxyl)
      pyrrolidinecarboxylate,
       3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxobutyl)-2-
      pyrrolidinecarboxylate,
        3,3-Diphenyl-1-propvl (2S)-1-cyclohexylglyoxyl-2-
      pyrrolidinecarboxylate,
        3,3-Diphenyl-1-propyl (2S)-1-(2-thienyl)glyoxyl-2-
 25
      pyrrolidinecarboxylate, and pharmaceutically acceptable salts,
      hydrates, and mixtures thereof.
```

17. A method of treating hair loss which comprises: administering to an animal an effective amount of a nonimmunosuppressive pyrrolidine carboxylate compound.

13. The method of claim 17 wherein the pyrrolidine carboxylate is a compound of the formula:

Opin ?

$$0 = \frac{1}{R}$$

I

5 wherein

 R_1 is selected from the group consisting of a C_1 - C_9 straight or branched chain alkyl or alkenyl group optionally substituted with C_3 - C_9 cycloalkyl, C_3 or C_9 cycloalkyl, C_9 - C_7 cycloalkenyl, Ar_1 , where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C_1 - C_4 alkyl, C_1 - C_4 alkenyl, or hydroxy, where Ar_1 is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino:

- X is selected from the group consisting of oxygen, sulphur, methylene (CH_2) , or H_2 ;
- Y is selected from the group consisting of oxygen or NR_2 , where R_2 is hydrogen or C^1 - C_6 alkyl; and

Z is selected from the group consisting of C_2 - C_6 straight or branched chain alkyl or alkenyl,

wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_1 - C_8 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight or unbranched alkyl or alkenyl chain, and Ar_2 is selected from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino; Z may also be the fragment:

wherein

5

10

1-1

United the second of the

20

- R₃ is a C₁-C₉ straight or branched alkyl / #₁-C₈ optionally substituted with C₃-C₈ cycloalkyl, or Ar₁ as defined above, and unsubstituted Ar₁;
- $\rm X_2$ is O or NR₅, where R₅ is selected from the group consisting of hydrogen, $\rm C_1\text{-}C_6$ straight or branched alkyl and alkenyl;
- R_4 is selected from the group consisting of phenyl, benzyl, C_1 - C_5 straight or branched alkyl or alkenyl, and C_1 - C_5 straight or branched alkyl or alkenyl substituted with phenyl; or pharmaceutically

acceptable salts or hydrates thereof.

19. The method of claim 17 wherein the pyrrolidine carboxylate is a compound of the formula:

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

II

5 wherein

R₁ is a C₁-C₉ straight or branched chain alkyl or alkenyl group optionally substituted with C₃-C₉ cycloalkyl, C₃ or C₅ cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁, where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl, or hydroxy, and where Ar₁ is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched alkyl or alkenyl, C₁-C₄ alkoxy or C₁-C₄ alkenyloxy, phenoxy, benzyloxy, and amino;

20

purh purk great series prime purch prime p

is a C_2 - C_6 straight or branched chain alkyl or alkenyl, wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_3 - C_8 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight or unbranched

1.5

Marie Marie

15¹

Marie and the state of the stat

111

į.

alkyl or alkenyl chain, or Ar₂ where Ar₂ is selected from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino; or pharmaceutically acceptable salts or hydrates thereof.

20. The method of claim 17 wherein the pyrrolidine carboxylate compound is selected from the group consisting of:

3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-phenyl-1-prop-2-(E)-enyl (2S)-1-(3,3,-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(3,4,5-trimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(3,4,5-trimethoxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-

dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(4,5-methylenedioxyphenyl)-1-propyl(2S)-1-(3,3,dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-(4,5-methylenedioxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-cyclohexyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

3-cyclohexyl-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,

```
(1R)-1,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-
                  dioxopentyl)-2-pyrrolidinecarboxylate,
                     3-phenyl-1-propyl (2S)-1-(1,2-dloxo-2-[2-furanyl])ethyl-2-
                  pyrrolidinecarboxylate,
                  3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thienyl])entyl-2-
     5
                 pyrrolidinecarboxylate,
                    3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thiazolyl])ethyl-2-
                 pyrrolidinecarboxylate,
                  3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2,phenyl)ethyl-2-
 10
                 pyrrolidinecarboxylate,
                   3-(2,5-dimethoxyphenyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-
                 dioxopentyl)-2-pyrrolidinecarboxylate,
                   3-(2,5-dimethoxyphenyl)-1-prop-2-(E)-enyl(2S)-1-(3,3-dimethyl-
 T
                 1,2-dioxopentyl)-2-pyrrolidinecarboxylate, .
                  2-(3,4,5-trimethoxyphenyl)-1-ethyl (2S)-1-(3,3-dimethyl-1,2-
                dioxopentyl)-2-pyrrolidinecarboxylate,
    IJ
                   3-(3-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
   The state of the s
                pyrrolidinecarboxylate,
                  3-(2-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
20
               pyrrolidinecarboxylate,
                  3-(4-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                pyrrolidinecarboxylate,
                  3-phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-
               pyrrolidinecarboxylate,
             3-phenyl-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-
25
               pyrrolidinecarboxylate,
```

3-phenyl-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-dioxoethyl)-2-

pyrrolidinecarboxylate,

- 3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-dioxoethyl)-2-pvrrolidinecarboxylate,
- 3-(3-Pyridyl)-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
- 5 3,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2pvrrolidinecarboxylate,
 - 3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
 - 3-(3-Pyridyl)-1-propyl (2S)-N-([2-thienyl]glyoxyl) pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxobutyl)-2-pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-cyclohexylglyoxyl-2-pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-(2-thienyl)glyoxyl-2-pyrrolidinecarboxylate, and pharmaceutically acceptable salts, hydrates, and mixtures thereof.
 - 21. A method of treating hair loss associated with cancer therapy, wherein the cancer therapy is selected from the group consisting of radiation and chemotherapy, wherein said method comprises: administering to an animal an effective amount of a non-immunosuppressive pyrrolidine carboxylate compound.

15%

22. The method of claim 21 wherein the pyrrolidine carboxylate is a compound of the formula:

 $\begin{array}{c|c}
 & Y \longrightarrow Z \\
 & X \\
\end{array}$

I

wherein

5

 R_1 is selected from the group consisting of a C_1 - C_9 straight or branched chain alkyl or alkenyl group optionally substituted with C_3 - C_8 cycloalkyl, C_1 or C_9 cycloalkyl, C_9 - C_9 cycloalkenyl, Ar_1 , where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C_1 - C_4 alkyl, C_1 - C_4 alkenyl, or hydroxy, where Ar_1 is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thianyl, 3-thianyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_4 straight or branched alkyl or alkenyl, C_1 - C_4 alkoxy or C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino:

- X is selected from the group consisting of oxygen, sulphur, methylene (CH_2), or H_2 ;
- Y is selected from the group consisting of oxygen or NR_2 , where R_2 is hydrogen or C^1 - C_5 alkyl; and
- Z is selected from the group consisting of C_2 - C_4 straight

party years given and party their street party that the street will be street to the street with the street that the street th

10

5

or branched chain alkyl or alkenyl,

wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_1 - C_8 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight or unbranched alkyl or alkenyl chain, and Ar_2 is selected from the group consisting of 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1 - C_6 straight or branched alkyl or alkenyl, C_1 - C_4 alkenyloxy, phenoxy, benzyloxy, and amino; Z may also be the fragment:

wherein

- R_3 is a C_1 - C_9 straight or branched alkyl $\#_1$ - C_8 optionally substituted with C_3 - C_8 cycloalkyl, or Ar_1 as defined above, and unsubstituted Ar_1 ;
- $\rm X_2$ is C or NR₅, where R₅ is selected from the group consisting of hydrogen, C₁-C₆ straight or branched alkyl and alkenyl;
- R₄ is selected from the group consisting of phenyl, benzyl, C_1 - C_5 straight or branched alkyl or alkenyl, and C_1 - C_5 straight or branched alkyl or alkenyl substituted with phenyl; or pharmaceutically acceptable salts or hydrates thereof.

25

23. The method of claim 21 wherein the pyrrolidine carboxylate is a compound of the formula:

II

wherein

5

R₁ is a C₁-C₉ straight or branched chain alkyl or alkenyl group optionally substituted with C₃-C₉ cycloalkyl, C₃ or C₅ cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁, where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl, or hydroxy, and where Ar₁ is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched alkyl or alkenyl, C₁-C₄ alkoxy or C₁-C₄ alkenyloxy, phenoxy, benzyloxy, and amino;

20

is a C_2 - C_6 straight or branched chain alkyl or alkenyl, wherein the alkyl chain is substituted in one or more positions with Ar_1 as defined above, C_2 - C_8 cycloalkyl, cycloalkyl connected by a C_1 - C_6 straight or unbranched alkyl or alkenyl chain, or Ar_2 where Ar_2 is selected

```
pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one
                                             to three substituents which are independently selected
                                          from the group consisting of hydrogen, halo, hydroxyl,
  5
                                             nitro trifluoromethyl, C1-C5 straight or branched alkyl
                                             or alkenyl, C<sub>1</sub>-C<sub>4</sub> alkoxy or C<sub>1</sub>-C<sub>4</sub> alkenyloxy, phenoxy,
                                             benzyloxy, and amino; or pharmaceutically acceptable
                                              salts or hydrates thereof.
10
                                             The method of claim 21 wherein the pyrrolidine
                 carboxylate compound is selected from the group consisting of:
                                                                              (2S) -1 - (3, 3 - dimethyl - 1, 2 - dioxopentyl) - 2 -
                    3-phenyl-1-propyl
from the thirt with the out of the thirt has
                 pyrrolidinecarboxylate,
                     3-phenyl-1-prop-2-(E)-enyl (2S)-1-(3,3,-dimethyl-1,2-
                 dioxopentyl) - 2 - pyrrolidinecarboxylate,
                    3 - (3, 4, 5 - \text{trimethoxyphenyl}) - 1 - \text{propyl} (2S) -1 - (3, 3 - \text{dimethyl} - 1, 2 - \text{dimethyl})
   Half H B Bridg Hell
                 dioxopentyl) - 2 - pyrrolidinecarboxylate,
                     3 - (3, 4, 5 - trimethoxyphenyl) - 1 - prop - 2 - (E) - enyl (2S) - 1 - (3, 3 - 4, 5 - trimethoxyphenyl) - 1 - prop - 2 - (E) - enyl (2S) - 1 - (3, 3 - 4, 5 - trimethoxyphenyl) - 1 - prop - 2 - (E) - enyl (2S) - 1 - (3, 3 - 4, 5 - trimethoxyphenyl) - 1 - prop - 2 - (E) - enyl (2S) - 1 - (3, 3 - 4, 5 - trimethoxyphenyl) - 1 - prop - 2 - (E) - enyl (2S) - 1 - (G) 
    dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
    ļ.,
20
                     3-(4,5-methylenedioxyphenyl)-1-propyl(2S)-1-(3,3,dimethyl-1,2-
                  dioxopentyl) - 2 - pyrrolidinecarboxylate,
                     3-(4,5-methylenedioxyphenyl)-1-prop-2-(E)-enyl (2S)-1-(3,3-
                  dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
                     3-cyclohexyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
 25
                 pyrrolidinecarboxvlate,
```

from the group consisting of 2-indoly1, 3-indoly1, 2-

furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 2-

3-cyclohexyl-1-prop-2-(E)-enyl (2S)-1-(3,3-dimethyl-1,2-

(1R) - 1, 3 - diphenyl - 1 - propyl (2S) - 1 - (3, 3 - dimethyl - 1, 2 -

dioxopentyl) - 2 - pyrrolidinecarboxylate,

```
dioxopentyl)'-2-pyrrolidinecarboxylate,
                  3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-furanyl])ethyl-2-
               pyrrolidinecarboxylate,
                 3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thienyl])entyl-2-
  5
               pyrrolidinecarboxylate,
                   3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2-[2-thiazolyl])ethyl-2-
                pyrrolidinecarboxylate,
                   3-phenyl-1-propyl (2S)-1-(1,2-dioxo-2,phenyl)ethyl-2-
                pyrrolidinecarboxylate,
10
                   3-(2,5-dimethoxyphenyl)-1-propyl
                                                                                                                   (2S)-1-(3,3-dimethyl-1,2-
                dioxopentyl) - 2 - pyrrolidinecarboxylate,
                   3-(2,5-dimethoxyphenyl)-1-prop-2-(E)-enyl(2S)-1-(3,3-dimethyl-
pide grass error grove grave grass grass and are found in grave grass and a few of the grass grass and a few of the grass country and the found in the found in the found in the few of the grass gra
                 1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
                   2-(3,4,5-trimethoxyphenyl)-1-ethyl (2S)-1-(3,3-dimethyl-1,2-
                dioxopentyl) - 2 - pyrrolidinecarboxylate,
                   3-(3-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                pyrrolidinecarboxylate,
                   3-(2-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                 pyrrclidinecarboxylate,
 20
                    3-(4-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-
                pyrrolidinecarboxylate,
                    3-phenyl-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-
                 pyrrolidinecarboxylate,
                    3-phenyl-1-propyl (25)-1-(2-tert-butyl-1,2-dioxoethyl)-2-
 25
                 pyrrolidinecarboxylate,
                    3-phenyl-1-propyl (2S)-1-(2-cyclohexylethyl-1,2-dioxoethyl)-2-
                 pyrrolidinecarboxylate,
```

(2S)-1-(2-cyclohexylethyl-1,2-

3-(3-Pyridyl)-1-propyl

```
dioxoethyl) - 2 - pyrrolidinecarboxylate,
```

- 3-(3-Pyridyl)-1-propyl (2S)-1-(2-tert-butyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
- 3,3-diphenyl-1-propyl (25)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate,
- 3-(3-Pyridyl)-1-propyl (2S)-1-(2-cyclohexyl-1,2-dioxoethyl)-2-pyrrolidinecarboxylate,
- 3-(3-Pyridyl)-1-propyl (2S)-N-([2-thienyl]glyoxyl) pyrrolidinecarboxylate,
- 3,3-Diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxobutyl)-2-pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (2S)-1-cyclohexylglyoxyl-2-pyrrolidinecarboxylate,
 - 3,3-Diphenyl-1-propyl (25)-1-(2-thienyl)glyoxyl-2-pyrrolidinecarboxylate, and pharmaceutically acceptable salts, hydrates, and mixtures thereof.